For the quarter ending 2025-09-30, CRVO made $322,569 in revenue. -$7,720,032 in net income. Net profit margin of -2393.30%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Grant revenue | 322,569 | 1,757,724 | 1,917,491 | 1,939,751 |
| Research and development | 6,040,442 | 5,108,625 | 4,837,798 | 5,125,097 |
| General and administrative | 2,326,326 | 3,265,374 | 2,382,577 | 2,210,927 |
| Total operating expenses | 8,366,768 | 8,373,999 | 7,220,375 | 7,336,024 |
| Loss from operations | -8,044,199 | -6,616,275 | -5,302,884 | -5,396,273 |
| Other expense | -1,227 | -10,256 | -135 | -3,440 |
| Interest income | 318,787 | 368,127 | 408,985 | 646,172 |
| Total other income, net | 317,560 | 357,871 | 408,850 | 642,732 |
| Net loss | -7,726,639 | -6,258,404 | -4,894,034 | -4,753,541 |
| Net unrealized gain (loss) on marketable securities | 6,607 | -22,006 | -34,974 | 142,864 |
| Total comprehensive loss | -7,720,032 | -6,280,410 | -4,929,008 | -4,610,677 |
| Diluted eps | - | - | - | -0.55 |
| Diluted average shares | - | - | - | 8,702,764 |
| Net loss per share of common stock, basic and diluted (in dollars per share) | -0.84 | -0.7 | -0.56 | -0.55 |
| Weighted average shares outstanding, basic and diluted (in shares) | 9,252,719 | 8,950,521 | 8,702,719 | 8,702,764 |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)